ArticleJournal of asthma and allergy2026
Drug Patterns and Economic Costs Among Patients with Hereditary Angioedema.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: This study explored real-world patterns of subcutaneous (SC) long-term prophylaxis (LTP), prescriptions for on-demand treatment (ODT), and treatment-related expenditures among patients with hereditary angioedema (HAE). Methods: This study was conducted using a retrospective cohort design and US healthcare claims database (02/23/18-06/30/22). Study population included patients aged ≥12 years who initiated SC LTP with C1-esterase inhibitor (C1-INH-SC) or lanadelumab for HAE management. Study measures were evaluated from the date of LTP initiation through the last date of health plan enrollment or the study period. Study measures included LTP adherence (medication possession ratio [MPR]), LTP discontinuation (gap in drug supply ≥60 days), annualized number of ODT prescriptions, and annualized treatment-related expenditures (ie., ODT prescriptions and emergent care [all-cause hospitalizations and emergency department (ED) visits]). Measures were summarized using means, percentages, and 95% confidence intervals (CI). Results: Study population included 196 patients (C1-INH-SC: N=65; lanadelumab: N=131); mean age was 39 years and 69% were female. During a mean follow-up of 19 months, MPR for LTP was 73% (CI: 68-77) and LTP discontinuation was 48% (41-55). Mean annualized number of ODT prescriptions was 3.8 (3.6-4.1) per patient, and mean annualized treatment-related expenditures totaled $209,547 (133,460-325,453) per patient, including $200,886 (124,792-317,983) for ODT prescriptions, $7,299 (3,408-12,214) for hospitalizations and $1,363 (859-1,959) for ED visits. Conclusion: Despite the availability of SC LTP for the management of HAE, adherence was suboptimal, almost 50% of patients discontinued prophylaxis, and treatment-related expenditures were high. Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.